Jay Stamatis Traded the Mega-Deal Table for a Biotech With Two Shots on Goal

After more than eight years shaping AbbVie’s pipeline, the history major turned biotech dealmaker is now running MBrace Therapeutics - where the wager is on novel targets, disciplined development and knowing which risks are worth taking.